AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

Rakon stock-price climb triggers watchdog review
Markets

Rakon stock-price climb triggers watchdog review

Rakon shares rose almost 9% on Wednesday but spiked even higher during the day.

Fisher Funds backs Summerset in rejecting covenant waiver claims
Markets

Fisher Funds backs Summerset in rejecting covenant waiver claims

Summerset is compliant with all lending covenants and obligations.

Critical minerals miner plans 2026 NZX listing
Primary Sector

Critical minerals miner plans 2026 NZX listing

The company plans to raise $20m from retail investors in mid-2026.

Genesis backs Huntly longevity as renewables pipeline expands
Markets

Genesis backs Huntly longevity as renewables pipeline expands

Huntly is cash-positive in every scenario to FY35 as Genesis expands renewables.